Optimal Treatment Sequencing in Relapsed/Refractory Multiple Myeloma

Phase 1 data demonstrate enduring responses with ISB 2001 among patients with relapsed/refractory multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

Final analysis data from the phase 3 ALCYONE trial support using frontline daratumumab-containing regimens for those with transplant-ineligible NDMM.